Jude Onyia, Chief Scientific Officer of Neurocrine Biosciences Inc., filed a Form 4 with the SEC on September 15, 2026, disclosing changes in beneficial ownership of common stock stemming from the vesting of performance restricted stock units on September 11, 2026.

Key Highlights

  • Reporting person: Jude Onyia, Chief Scientific Officer of Neurocrine Biosciences Inc. (NASDAQ:NBIX)
  • PRSU vesting: 3,587 shares of common stock were acquired at $0 per share on September 11, 2026, following certification that a performance metric had been achieved
  • Tax withholding: 1,936 shares were withheld by the company to satisfy tax withholding obligations on the PRSU vesting, at a price of $156.22 per share; no shares were sold
  • Post-transaction ownership: Onyia directly and beneficially owns 22,647 shares of common stock following the reported transactions
  • Filing date: September 15, 2026, signed by Darin Lippoldt as Attorney-in-Fact

PRSU Vesting and Share Withholding at Neurocrine Biosciences

According to the filing, Onyia was previously granted performance restricted stock units, referred to as PRSUs, that vest upon the achievement of certain performance metrics. The filing states that the achievement of one such metric was certified on September 11, 2026, triggering the acquisition of 3,587 shares of common stock at a price of $0 under transaction code "A." Neurocrine Biosciences is a neuroscience-focused biopharmaceutical company, and Onyia serves in the role of Chief Scientific Officer, a position that carries reporting obligations under Section 16(a) of the Securities Exchange Act of 1934.

In connection with the vesting event, the filing discloses that 1,936 shares were withheld by Neurocrine Biosciences, Inc. to satisfy tax withholding requirements, recorded under transaction code "F" at a per-share price of $156.22. The filing notes explicitly that "No shares were sold." Following both transactions, Onyia's direct beneficial ownership in common stock is reported as 22,647 shares. The form was filed by one reporting person and covers non-derivative securities only, with no derivative securities activity reported in Table II.

What Was Disclosed

The filing reported two transactions in Neurocrine Biosciences common stock on September 11, 2026: the vesting of 3,587 PRSUs acquired at $0, and the withholding of 1,936 shares at $156.22 each to cover tax obligations, leaving Onyia with direct beneficial ownership of 22,647 shares.